It is a widely understood that androgen deprivation therapy (ADT) causes adverse side effects and events. Some researchers believe that the ADT-induced alterations in lipid and glucose metabolism may be race-dependent. To evaluate this concern the researchers recruited Japanese men with newly diagnosed prostate cancer who also underwent at least one year of ADT. They [...]
Please complete this ten minute, four question, anonymous survey about your thoughts around prostate cancer support and advocacy. Click>>> https://www.surveymonkey.com/s/CCRNTQP Your answers will help us to plan future prostate cancer support and advocacy actions on your behalf. Please feel encouraged to contact me by email at joel@malecare.org with any questions or concerns about this brief survey.
Current Prognostic models for overall survival (OS) for men with metastatic castration-resistant prostate cancer (mCRPC) have become dated. They don’t adequately reflect the many new drugs used in clinical practice. To develop a relevant model data from a phase III trial of 1,050 men with mCRPC were used (Cancer and Leukemia Group B CALGB-90401 [Alliance]) was evaluated. [...]
Malecare announces the addition of our latest and informative teleconference about Immunotherapy and Advanced Prostate Cancer. Joining me in the conference is Dr. Nicholas J. Vogelzang, M.D., a medical oncologist with the Comprehensive Cancer Centers of Nevada (CCCN) and serves as chair and site research leader, and as medical director of the Developmental Therapeutics Committee and Member [...]
We all are subject to developing depression and prostate cancer survivors are subject to a large share of it. Besides dealing with the everyday issues of living our life, we also are hounded by our diagnosis. However, it is important to understand that there are everyday types of depression and what is referred to as [...]